Dermatology Diagnostic Developer, MELA Sciences, to Host Q4 Conference Call Monday, March 17, 2014 at 4:30 pm ET

MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, will release its fourth quarter and full year 2013 results on Monday, March 17, 2014, after the market’s close. MELA Sciences President and CEO, Rose Crane will host a conference call that day at 4:30pm ET to review the results and provide general business update.

To participate in the conference call, please dial:

Domestic toll-free:

[phone]

International:

[phone]

 

Live Webcast & Replay:A live webcast will be available at: www.melasciences.com/investors/homeIf you are unable to participate during the live call and webcast, a replay will be archived and available for approximately 90 days after the call.

About MELA Sciences, Inc. www.melasciences.comMELA Sciences is a medical device company developing dermatology diagnostics utilizing state-of-the-art optical imaging. The flagship product is MelaFind®, an FDA, PMA and CE Mark approved, non-invasive diagnostic tool to aid dermatologists in melanoma evaluation and diagnosis. MelaFind® uses a variety of visible to near-infrared light waves to evaluate skin lesions from the surface to 2.5 mm beneath the skin. It provides images and data on the relative disorganization of a lesion's cell structure that provides substantial additional perspective to aid melanoma diagnosis. MELA is also exploring new potential uses for its core imaging technology and algorithms.

Please follow us:

Twitter:

@MELASciencesIR or @MelaFind

Facebook:

www.facebook.com/MelaFind

StockTwits:

@MELASciencesIR

BoardVote:

MELA Sciences

MediaMELA Sciences, Inc.Diana Garcia Redruello, [e-mail] GlobalToni Trigiani, David Collins, [e-mail]